Bernstein Remains a Buy on BeOne Medicines AG (ONC)
BeOne Medicines AG (NASDAQ:ONC) is one of the High Growth International Stocks to Buy Now. On February 9, Rebecca Liang from Bernstein reiterated a Buy rating on the stock with a $414 price target. Earlier, on February 4, Barclays also reiterated a Buy rating on BeOne Medicines AG (NASDAQ:ONC) and raised the price target from $385 to $394.
The bullish sentiment follows the first-in-world approval of BeOne’s Sonrotoclax in China to treat adults with two hard-to-treat blood cancers. These include relapsed/refractory mantle cell lymphoma (MCL) and relapsed/refractory chronic lymphocytic leukemia (CLL). The approval in China was based on the MCL study and CLL/SLL study presented at the 2025 ASH conference.
The MCL study demonstrated 52.4% overall response rate per independent review, and the CLL/SLL study showed 77% ORR per independent review. Management noted that the approval in China is part of a global rollout strategy.
Rebecca Liang from Bernstein believes BeOne Medicines AG (NASDAQ:ONC) to be undervalued considering its pipeline. She noted that “the pipeline is not recognized by the market,” and highlighted Sonrotoclax as “potential best-in-class status.”
BeOne Medicines AG (NASDAQ:ONC), based in Switzerland, is a global oncology company focused on discovering and developing innovative cancer treatments for hematology and solid tumors worldwide.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
British Pound gains as US Dollar weakens despite hawkish Fed, geopolitical tensions
Volatility Divergence Between Individual Stocks and Index! Popular US Stock Trading: Go Long on Stock Options, Hedge with Index Options
With the divergence in the AI narrative, drastic fluctuations in oil prices, and U.S. Treasury yields soaring to a 20-year high, the degree of dispersion among S&P 500 constituents has risen to the 95th percentile in 30 years. As single-stock volatility continues to compress, entry costs have become relatively low, and the volatility gap between individual stocks and the index has widened again. This has opened a rare window for dispersed trading strategies such as "long single-stock options + short index options."
US Treasury yield curve approaches inversion! Is the bond market questioning the outlook for the US economy?
The U.S. Treasury yield curve is rapidly approaching the inversion threshold—the spread between the 10-year and 2-year yields has narrowed to historic lows, and bank stocks have responded with a technical correction. This warning signal, regarded as a "hard rule" for recession, is tearing apart market consensus: some are betting the curve will soon invert, while others firmly believe economic resilience will mitigate the risk. Amid ongoing Federal Reserve rate hikes, the outcome of this bond market game may reshape the narrative logic of the entire asset market.
From ICU to KTV! The Polarized "AI Narrative" Leaves Investors "Exhausted"
In just two weeks, the Nasdaq 100 experienced an extreme rollercoaster: first losing $600 billion in market value due to “AI threat” concerns, then rebounding to reclaim $3 trillion thanks to the viral Meta assistant. Analysts believe that market sentiment is swinging violently between fear and greed, detached from fundamentals. The turmoil has driven Nvidia’s valuation to a ten-year low, intensified the bull-bear divide, and the high volatility driven by narratives has become a long-term norm for investors. This week, Micron will release its financial report; regardless of the outcome, the sharp swings in market sentiment are unlikely to subside.
Crypto prices
More
